FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.

The surge in global cancer cases is raising serious concerns among experts. A recent study published in Monday in Cancer, a ...

Taken together, the BRACELET-1 results provide compelling support for the potential of pelareorep-based combination therapy to benefit patients with advanced or metastatic HR+/HER2- breast cancer.

During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...

FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer ...

In the oncology world, there’s been plenty to celebrate recently, with cancer deaths falling by 33% in the last 30 years.

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Oncolytics Biotech (ONCY – Research Report). The ...

Announced positive clinical results from BRACELET-1, its randomized Phase 2 study evaluating pelareorep in patients with HR+/HER2- advanced or metastatic breast cancer, reinforcing path to funding of ...

Breast cancer remains the most common invasive cancer diagnosed in women in the United States, accounting for about one in three new female cancers each ye | Cancer ...

Novartis announced this week that the FDA has approved ribociclib (marketed as Kisqali) for the treatment of people with ...

Novartis’ Kisqali receives US FDA approval to reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Thursday, September 19, 2024, 13:00 Hrs [IST] Novarti ...

Combining endocrine therapy with the dual HER2 blockade of trastuzumab and pertuzumab and the CDK4/6 inhibitor ribociclib ...